Annexon, Inc.
Quick facts
Phase 3 pipeline
- Tanruprubart · Other
- Vonaprument · Other
Phase 2 pipeline
- ANX007 · Neurology
ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Annexon, Inc.
What is Annexon, Inc.'s pipeline?
Annexon, Inc. has 2 drugs in Phase 3, 1 in Phase 2, 3 in Phase 1. Late-stage candidates include Tanruprubart, Vonaprument.
Related
- Sector hub: All tracked pharma companies